{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:54:12Z","timestamp":1791060852167,"version":"4.1.0"},"reference-count":181,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.omta.2026.201848","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:37:40Z","timestamp":1788881860000},"page":"201848","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical immunogenicity in rAAV gene therapy: Insights and implications"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8511-1065","authenticated-orcid":false,"given":"Nitish","family":"Gulve","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Bego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitesh","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilehuma","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Katebifar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Rajadhyaksha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2026.201848_bib1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1146\/annurev-virology-031413-085355","article-title":"AAV-Mediated Gene Therapy for Research and Therapeutic Purposes","volume":"1","author":"Samulski","year":"2014","journal-title":"Annu. Rev. Virol."},{"key":"10.1016\/j.omta.2026.201848_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/cells12050785","article-title":"Various AAV Serotypes and Their Applications in Gene Therapy: An Overview","volume":"12","author":"Issa","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.omta.2026.201848_bib3","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1016\/j.ymthe.2022.09.015","article-title":"AAV vectors: The Rubik's cube of human gene therapy","volume":"30","author":"Pupo","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201848_bib4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.omta.2026.201848_bib5","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1016\/j.cell.2021.08.028","article-title":"Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species","volume":"184","author":"Tabebordbar","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.omta.2026.201848_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975803","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"Ertl","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201848_bib7","doi-asserted-by":"crossref","first-page":"6459","DOI":"10.1182\/blood-2010-10-314518","article-title":"The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver","volume":"117","author":"Martino","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201848_bib8","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1172\/JCI68205","article-title":"CpG-depleted adeno-associated virus vectors evade immune detection","volume":"123","author":"Faust","year":"2013","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omta.2026.201848_bib9","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1089\/hum.2023.018","article-title":"Complement Activation by Adeno-Associated Virus-Neutralizing Antibody Complexes","volume":"34","author":"West","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201848_bib10","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nm1549","article-title":"CD8(+) T-cell responses to adeno-associated virus capsid in humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2026.201848_bib11","unstructured":"AAV Vectors in Gene Therapy - Pipeline Insight, 2024. (2024)."},{"key":"10.1016\/j.omta.2026.201848_bib12","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2026.201848_bib13","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3389\/fimmu.2014.00350","article-title":"Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions","volume":"5","author":"Basner-Tschakarjan","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201848_bib14","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-Associated Virus Vector\u2013Mediated Gene Transfer in Hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201848_bib15","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1111\/brv.12718","article-title":"Humoral immune responses to AAV gene therapy in the ocular compartment","volume":"96","author":"Whitehead","year":"2021","journal-title":"Biol. Rev. Camb. Phil. Soc."},{"key":"10.1016\/j.omta.2026.201848_bib16","doi-asserted-by":"crossref","first-page":"120ra15","DOI":"10.1126\/scitranslmed.3002865","article-title":"AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness","volume":"4","author":"Bennett","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omta.2026.201848_bib17","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1172\/JCI200316887","article-title":"Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer","volume":"111","author":"Mingozzi","year":"2003","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omta.2026.201848_bib18","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1146\/annurev.iy.12.040194.005015","article-title":"Tolerance, danger, and the extended family","volume":"12","author":"Matzinger","year":"1994","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.omta.2026.201848_bib19","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1172\/JCI37607","article-title":"The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice","volume":"119","author":"Zhu","year":"2009","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omta.2026.201848_bib20","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/hep.24625","article-title":"Toll\u2013Like Receptor 2\u2013Mediated Innate Immune Response in Human Nonparenchymal Liver Cells Toward Adeno\u2013Associated Viral Vectors","volume":"55","author":"H\u00f6sel","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.omta.2026.201848_bib21","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120474","article-title":"Double-stranded RNA innate immune response activation from long-term adeno-associated virus vector transduction","volume":"3","author":"Shao","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.omta.2026.201848_bib22","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3389\/fimmu.2020.00670","article-title":"Human Immune Responses to Adeno-Associated Virus (AAV) Vectors","volume":"11","author":"Ronzitti","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201848_bib23","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1128\/JVI.01990-07","article-title":"Complement is an essential component of the immune response to adeno-associated virus vectors","volume":"82","author":"Zaiss","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201848_bib24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/ni.3123","article-title":"Control of adaptive immunity by the innate immune system","volume":"16","author":"Iwasaki","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omta.2026.201848_bib25","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1182\/blood-2016-11-751040","article-title":"Plasmacytoid and conventional dendritic cells cooperate in crosspriming AAV capsid-specific CD8(+) T cells","volume":"129","author":"Rogers","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201848_bib26","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.ymthe.2019.11.011","article-title":"Type I IFN Sensing by cDCs and CD4(+) T Cell Help Are Both Requisite for Cross-Priming of AAV Capsid-Specific CD8(+) T Cells","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201848_bib27","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ymthe.2023.11.029","article-title":"TLR9-independent CD8(+) T cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling","volume":"32","author":"Kumar","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201848_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/v16101507","article-title":"Redundancy in Innate Immune Pathways That Promote CD8(+) T-Cell Responses in AAV1 Muscle Gene Transfer","volume":"16","author":"Li","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.omta.2026.201848_bib29","article-title":"Adeno-Associated Virus (AAV)-Mediated Gene Therapy for Duchenne Muscular Dystrophy: The Issue of Transgene Persistence","volume":"12","author":"Manini","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.omta.2026.201848_bib30","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1128\/CVI.05107-11","article-title":"Adeno-associated virus antibody profiles in newborns, children, and adolescents","volume":"18","author":"Calcedo","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.omta.2026.201848_bib31","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1089\/hum.2021.287","article-title":"Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A","volume":"33","author":"Klamroth","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201848_bib32","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.omtm.2019.05.014","article-title":"Prevalence of Anti-Adeno-Associated Virus Immune Responses in International Cohorts of Healthy Donors","volume":"14","author":"Kruzik","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201848_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101217","article-title":"Preexisting antibody assays for gene therapy: Considerations on patient selection cutoffs and companion diagnostic requirements","volume":"32","author":"Braun","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201848_bib34","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.omtm.2022.02.011","article-title":"Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerations","volume":"25","author":"Mendell","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201848_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.999021","article-title":"Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood","volume":"13","author":"Smith","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201848_bib36","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy","volume":"74","author":"Chand","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omta.2026.201848_bib37","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2023.01.010","article-title":"Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapy","volume":"31","author":"Schulz","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201848_bib38","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201848_bib39","doi-asserted-by":"crossref","DOI":"10.1172\/JCI143780","article-title":"Overcoming innate immune barriers that impede AAV gene therapy vectors","volume":"131","author":"Muhuri","year":"2021","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omta.2026.201848_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.666666","article-title":"T Cell-Mediated Immune Responses to AAV and AAV Vectors","volume":"12","author":"Ertl","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201848_bib41","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201848_bib42","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant","volume":"377","author":"George","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201848_bib43","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-Factor VIII Gene Transfer in Severe Hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201848_bib44","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5\u2013human factor IX in adults with hemophilia B","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201848_bib45","first-page":"3331","article-title":"101HEMB01 Is a Phase 1\/2 Open-Label, Single Ascending Dose-Finding Trial of DTX101 (AAVrh10FIX) in Patients with Moderate\/Severe Hemophilia B That Demonstrated Meaningful but Transient Expression of Human Factor IX (hFIX)","volume":"130","author":"Pipe","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201848_bib46","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.2019004625","article-title":"BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression","volume":"137","author":"Konkle","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201848_bib47","first-page":"3333","article-title":"Immune Responses in 101HEMB01, a Phase 1\/2 Open-Label, Single Ascending Dose-Finding Trial of DTX101 (AAVrh10FIX) in Patients with Severe Hemophilia B","volume":"130","author":"Calcedo","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201848_bib48","series-title":"A Phase 1\/2 Trial of Investigational Spk-8011 in Hemophilia a Demonstrates Durable Expression and Prevention of Bleeds","author":"High","year":"2018"},{"key":"10.1016\/j.omta.2026.201848_bib49","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/bloodadvances.2024015184","article-title":"Gene therapy for hemophilia B: results from the phase 1\/2 101HEMB01\/02 studies","volume":"9","author":"Pipe","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.omta.2026.201848_bib50","doi-asserted-by":"crossref","first-page":"10656","DOI":"10.1182\/blood-2022-163297","article-title":"BAX 335 Hemophilia B Gene Therapy Phase 1\/2 Clinical Trial: Long-Term Safety and Efficacy Follow-up","volume":"140","author":"Escobar","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201848_bib51","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/blood-2007-02-073304","article-title":"Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer","volume":"110","author":"Cao","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201848_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1371089","article-title":"Immune regulation and therapeutic application of T regulatory cells in liver diseases","volume":"15","author":"Ajith","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201848_bib53","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.3389\/fimmu.2019.02525","article-title":"Liver-Mediated Adaptive Immune Tolerance","volume":"10","author":"Zheng","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201848_bib54","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/mt.2011.33","article-title":"Nonredundant roles of IL-10 and TGF-beta in suppression of immune responses to hepatic AAV-factor IX gene transfer","volume":"19","author":"Hoffman","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201848_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26093988","article-title":"Liver Sinusoidal Endothelial Cells in the Regulation of Immune Responses and Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease","volume":"26","author":"Puri","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omta.2026.201848_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1328193","article-title":"Mechanisms underlying immunosuppression by regulatory cells","volume":"15","author":"Goldmann","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201848_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.719954","article-title":"Regulatory T-Cell Therapy in Liver Transplantation and Chronic Liver Disease","volume":"12","author":"Hann","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201848_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2017.12.002","article-title":"Liver induced transgene tolerance with AAV vectors","volume":"342","author":"Keeler","year":"2019","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.omta.2026.201848_bib59","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/bloodadvances.2024013000","article-title":"Induction of factor VIII tolerance by hemophilia gene transfer to eradicate factor VIII inhibitors","volume":"9","author":"Young","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.omta.2026.201848_bib60","doi-asserted-by":"crossref","DOI":"10.1172\/JCI173510","article-title":"Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies","volume":"134","author":"Salabarria","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omta.2026.201848_bib61","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMra020528","article-title":"THROMBOTIC MICROANGIOPATHIES","volume":"347","author":"MOAKE","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201848_bib62","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/sj.ki.5001535","article-title":"The molecular biology of thrombotic microangiopathy","volume":"70","author":"Tsai","year":"2006","journal-title":"Kidney Int."},{"key":"10.1016\/j.omta.2026.201848_bib63","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2215\/CJN.05830519","article-title":"Complement Activation and Thrombotic Microangiopathies","volume":"14","author":"Palomo","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.omta.2026.201848_bib64","unstructured":"Summary of the Risk Management Plan for Zolgensma\u00ae. 2023."},{"key":"10.1016\/j.omta.2026.201848_bib65","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement System Part I - Molecular Mechanisms of Activation and Regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201848_bib66","series-title":"4th Gene Therapy Immunogenicity Summit","article-title":"AAV-Associated Complement Activation in the Clinical Trial Setting","author":"Laforet","year":"2020"},{"key":"10.1016\/j.omta.2026.201848_bib67","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","article-title":"Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy","volume":"6","author":"Guillou","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.omta.2026.201848_bib68","doi-asserted-by":"crossref","DOI":"10.1161\/circ.144.suppl_1.10727","article-title":"Abstract 10727: Results from First-in-Human Clinical Trial of RP-A501 (AAV9:LAMP2B) Gene Therapy Treatment for Danon Disease","volume":"144","author":"Greenberg","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.omta.2026.201848_bib69","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41434-026-00609-1","article-title":"First-in-human nuclease-free homologous recombination-dependent gene editing in pediatric patients with methylmalonic acidemia: results of a phase 1\/2 study","volume":"33","author":"Bedoyan","year":"2026","journal-title":"Gene Ther."},{"key":"10.1016\/j.omta.2026.201848_bib70","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","article-title":"Thrombotic Microangiopathy Following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series","volume":"231","author":"Chand","year":"2021","journal-title":"J. Pediatr."},{"key":"10.1016\/j.omta.2026.201848_bib71","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jtct.2022.11.015","volume":"29","author":"Schoettler","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.omta.2026.201848_bib72","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/art.42681","article-title":"Clinical Evaluation and Management of Thrombotic Microangiopathy","volume":"76","author":"Leisring","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.omta.2026.201848_bib73","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70370","article-title":"Complement and transplant-associated thrombotic microangiopathy: Current and future approaches","volume":"10","author":"Cugno","year":"2026","journal-title":"HemaSphere"},{"key":"10.1016\/j.omta.2026.201848_bib75","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1016\/j.ymthe.2026.05.016","article-title":"Death following high-dose AAV9 gene therapy in a patient with advanced SMA-PME","volume":"34","author":"Boespflug-Tanguy","year":"2026","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201848_bib76","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.ymthe.2025.12.067","article-title":"Deaths in gene therapy of Duchenne muscular dystrophy and other diseases: Underlying mechanisms and mitigating strategies","volume":"34","author":"Duan","year":"2026","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201848_bib77","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1001263","article-title":"rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis","volume":"13","author":"Shen","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201848_bib78","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jpeds.2020.05.044","article-title":"Subacute Liver Failure Following Gene Replacement Therapy for Spinal Muscular Atrophy Type 1","volume":"225","author":"Feldman","year":"2020","journal-title":"J. Pediatr."},{"key":"10.1016\/j.omta.2026.201848_bib79","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/s41587-020-0642-9","article-title":"High-dose AAV gene therapy deaths","volume":"38","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omta.2026.201848_bib80","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s11901-023-00624-5","article-title":"Hepatotoxicity in Adeno-Associated Viral Vector Gene Therapy","volume":"22","author":"Jagadisan","year":"2023","journal-title":"Curr. Hepat. Rep."},{"key":"10.1016\/j.omta.2026.201848_bib81","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/joa.12083","article-title":"Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease?","volume":"224","author":"Shababi","year":"2014","journal-title":"J. Anat."},{"key":"10.1016\/j.omta.2026.201848_bib82","unstructured":"Package Insert - ZOLGENSMA."},{"key":"10.1016\/j.omta.2026.201848_bib83","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.jtha.2024.12.038","article-title":"Safety and efficacy of valoctocogene roxaparvovec with prophylactic glucocorticoids: 1-year results from the phase 3b, single-arm, open-label GENEr8-3 study","volume":"23","author":"Ozelo","year":"2025","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.omta.2026.201848_bib84","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","article-title":"Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A","volume":"385","author":"George","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201848_bib85","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1182\/bloodadvances.2024013059","article-title":"Optimizing liver health before and after gene therapy for hemophilia A","volume":"8","author":"Ragni","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.omta.2026.201848_bib86","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201848_bib134","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201848_bib87","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/jth.12412","article-title":"Human liver sinusoidal endothelial cells but not hepatocytes contain factor VIII","volume":"12","author":"Shahani","year":"2014","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.omta.2026.201848_bib88","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2016.64","article-title":"Overexpression of factor VIII after AAV delivery is transiently associated with cellular stress in hemophilia A mice","volume":"3","author":"Lange","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201848_bib89","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.omtm.2020.07.005","article-title":"Induction of ER Stress by an AAV5 BDD FVIII Construct Is Dependent on the Strength of the Hepatic-Specific Promoter","volume":"18","author":"Fong","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201848_bib90","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41591-022-01751-0","article-title":"Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A","volume":"28","author":"Fong","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2026.201848_bib91","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S1474-4422(23)00313-7","article-title":"Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial","volume":"22","author":"Shieh","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omta.2026.201848_bib92","doi-asserted-by":"crossref","DOI":"10.1172\/JCI166275","article-title":"Loss of Mtm1 causes cholestatic liver disease in a model of X-linked myotubular myopathy","volume":"133","author":"Karolczak","year":"2023","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omta.2026.201848_bib93","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3233\/JND-210712","article-title":"Intrahepatic Cholestasis Is a Clinically Significant Feature Associated with Natural History of X-Linked Myotubular Myopathy (XLMTM): A Case Series and Biopsy Report","volume":"9","author":"Molera","year":"2022","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.omta.2026.201848_bib94","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adr1483","article-title":"AAV8 gene therapy and dietary insults together precipitate cholestatic liver disease in a mouse model of X-linked myotubular myopathy","volume":"18","author":"Pannia","year":"2026","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omta.2026.201848_bib95","article-title":"Immunotherapy and Gene Therapy: New Challenges in the Diagnosis and Management of Drug-Induced Liver Injury","volume":"12","author":"Delire","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.omta.2026.201848_bib96","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.omtm.2021.05.012","article-title":"Monitoring cell-mediated immune responses in AAV gene therapy clinical trials using a validated IFN-\u03b3 ELISpot method","volume":"22","author":"Patton","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201848_bib97","doi-asserted-by":"crossref","DOI":"10.1177\/22143602261424971","article-title":"Sirolimus for the treatment of steroid-refractory hepatotoxicity following AAV gene therapy in patients with Duchenne muscular dystrophy","author":"Leon-Astudillo","year":"2026","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.omta.2026.201848_bib98","doi-asserted-by":"crossref","DOI":"10.3390\/jcdd9120427","article-title":"Long COVID-19 Myocarditis and Various Heart Failure Presentations: A Case Series","volume":"9","author":"Rohun","year":"2022","journal-title":"J. Cardiovasc. Dev. Dis."},{"key":"10.1016\/j.omta.2026.201848_bib99","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMc2212912","article-title":"Dystrophin Immunity after Gene Therapy for Duchenne\u2019s Muscular Dystrophy","volume":"388","author":"B\u00f6nnemann","year":"2023","journal-title":"N. Engl. J. Med. Overseas. Ed."},{"key":"10.1016\/j.omta.2026.201848_bib100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1094279","article-title":"Immune transgene-dependent myocarditis in macaques after systemic administration of adeno-associated virus expressing human acid alpha-glucosidase","volume":"14","author":"Hordeaux","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201848_bib101","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jacc.2024.10.080","article-title":"2024 ACC Expert Consensus Decision Pathway on Strategies and Criteria for the Diagnosis and Management of Myocarditis: A Report of the American College of Cardiology Solution Set Oversight Committee","volume":"85","author":"Drazner","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.omta.2026.201848_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2023.131617","article-title":"Gene therapy vector-related myocarditis","volume":"398","author":"Silver","year":"2024","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.omta.2026.201848_bib103","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.950651","article-title":"Drug development progress in duchenne muscular dystrophy","volume":"13","author":"Deng","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.omta.2026.201848_bib104","series-title":"ROCTAVIAN (Valoctocogene Roxaparvovec-Rvox)[package Insert]","year":"2023"},{"key":"10.1016\/j.omta.2026.201848_bib105","series-title":"King of Prussia, PA: CSL Behring","year":"2022"},{"key":"10.1016\/j.omta.2026.201848_bib106","unstructured":"BEQVEZTM (Fidanacogene Elaparvovec-Dzkt) [[package Insert]. New York, NY: Pfizer Inc.; 2024."},{"key":"10.1016\/j.omta.2026.201848_bib107","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s40264-021-01107-6","article-title":"Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy","volume":"44","author":"Day","year":"2021","journal-title":"Drug Saf."},{"key":"10.1016\/j.omta.2026.201848_bib108","series-title":"ELEVIDYS (Delandistrogene Moxeparvovec-Rokl)[package Insert]","year":"2023"},{"key":"10.1016\/j.omta.2026.201848_bib109","unstructured":"Proud C, M.C., Mercuri E, Muntoni F, Zaidman C, Dharia S, Mason S, Meng J, Murphy A, Palatinsky E, Reid C, et al. (2025). Long-term safety and tolerability of delandistrogene moxeparvovec in Duchenne muscular dystrophy: phase 1 to phase 3 clinical trials. 29th International Annual Congress of the World Muscle Society (WMS) 2024 - Neuromuscular Disorders."},{"key":"10.1016\/j.omta.2026.201848_bib110","author":"Therapeutics"},{"key":"10.1016\/j.omta.2026.201848_bib111","article-title":"Unexpected Death of a Duchenne Muscular Dystrophy Patient in an N-of-1 Trial of rAAV9-delivered CRISPR-transactivator","author":"Lek","year":"2023","journal-title":"medRxiv"},{"key":"10.1016\/j.omta.2026.201848_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2024.07.290","article-title":"410P GNT0004, Genethon's AAV8 vector-delivered microdystrophin gene therapy of Duchenne muscular dystrophy, first data of the phase I\/II part of the GNT-016-MDYF all-in-one clinical trial in ambulant boys","volume":"43","author":"Laugel","year":"2024","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omta.2026.201848_bib113","unstructured":"A Message From Pfizer On Our DMD Clinical Program [Internet]. 2021. Available from: [https:\/\/cureduchenne.org\/partner-news\/a-message-from-pfizer-on-our-dmd-clinical-program]."},{"key":"10.1016\/j.omta.2026.201848_bib114","series-title":"Luxturna [European public assessment report]: Novartis EuropharmLimited Vista Building","year":"2019"},{"key":"10.1016\/j.omta.2026.201848_bib115","series-title":"Zolgensma (onasemnogene abeparvovec) [European public assessment report]:Novartis Europharm Limited Vista Building","year":"2020"},{"key":"10.1016\/j.omta.2026.201848_bib116","article-title":"Rocket Pharmaceuticals announces positive gene expression, clinical biomarker and preliminary functional data from Phase 1 trial of RP-A501 for the treatment of Danon disease","year":"2020","journal-title":"Business Wire"},{"key":"10.1016\/j.omta.2026.201848_bib117","unstructured":"Astellas announces positive safety data from the FORTIS study of AT845 in adults with late-onset Pompe disease. Data presented at the 18th Annual WORLDSymposium 2022. Available from https:\/\/www.astellas.com\/en\/news\/25006."},{"key":"10.1016\/j.omta.2026.201848_bib119","first-page":"513","article-title":"Emerging Thrombotic Disorders Associated with Virus-Based Innovative Therapies: From VITT to AAV Gene Therapy\u2013Related Thrombotic Microangiopathy","volume":"125","author":"Benemei","year":"2024","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.omta.2026.201848_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2024.07.475","article-title":"258P Safety and tolerability of onasemnogene abeparvovec for patients with spinal muscular atrophy weighing\u2264 17 kg and\u2264 24 months old: phase 4 OFELIA study","volume":"43","author":"Zanoteli","year":"2024","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omta.2026.201848_bib121","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1186\/s13023-024-03326-3","article-title":"Real-world multidisciplinary outcomes of onasemnogene abeparvovec monotherapy in patients with spinal muscular atrophy type 1: experience of the French cohort in the first three years of treatment","volume":"19","author":"Desguerre","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omta.2026.201848_bib122","article-title":"Danon Disease phase 1 RP-A501 results: the first single-dose intravenous (IV) gene therapy with recombinant adeno-associated virus (AAV9:LAMP2B) for a monogenic cardiomyopathy European Society of Gene and Cell Therapy (ESGCT) Annual Congress","author":"Greenberg","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.omta.2026.201848_bib123","first-page":"80","article-title":"Demonstration of nuclease-free genome editing (GeneRide) in pediatric patients with methylmalonic acidemia","volume":"32","author":"Payton","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201848_bib124","unstructured":"FDA. BLA Clinical Review Memorandum: Delandistrogene Moxeparvovec-Rokl 2023."},{"key":"10.1016\/j.omta.2026.201848_bib125","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa2307952","article-title":"Intrathecal gene therapy for giant axonal neuropathy","volume":"390","author":"Bharucha-Goebel","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201848_bib126","article-title":"Efficacy and safety of onasemnogene abeparvovec in children with spinal muscular atrophy type 1: real-world evidence from 6 infusion centres in the United Kingdom","volume":"37","author":"Gowda","year":"2024","journal-title":"Lancet Reg. Health. Eur."},{"key":"10.1016\/j.omta.2026.201848_bib127","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3233\/JND-230122","article-title":"Real-world outcomes in patients with spinal muscular atrophy treated with onasemnogene abeparvovec monotherapy: findings from the RESTORE registry","volume":"11","author":"Servais","year":"2024","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.omta.2026.201848_bib128","doi-asserted-by":"crossref","unstructured":"Flanigan, K.M., Smith, N.J., Couce, M.L., Escolar, M., Truxal, K.V., McBride, K.L., de Castro, M.J., Fuller, M., Paneda, A., and Ruiz, J. (2021). Updated Results of Transpher A, a Multicenter, Single-Dose, Phase 1\/2 Clinical Trial of ABO-102 Gene Therapy for Sanfilippo Syndrome Type A (Mucopolysaccharidosis IIIA). MOLECULAR THERAPY. CELL PRESS 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA.","DOI":"10.1016\/S1096-7192(21)00288-2"},{"key":"10.1016\/j.omta.2026.201848_bib129","series-title":"European Society of Gene and Cell Therapy (ESGCT) Annual Congress 2024","article-title":"Results from the CANaspire Gene Therapy Trial for Canavan Disease: Safety, Biomarker, Imaging, and Clinical Outcome Data from the Completed Low-dose Cohort","author":"Eichler","year":"2024"},{"key":"10.1016\/j.omta.2026.201848_bib130","unstructured":"A Phase I\/2, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of SB-913, a rAAV2\/6-Based Gene Transfer in Subjects with Mucopolysaccharidosis II (MPS II). (2017)."},{"key":"10.1016\/j.omta.2026.201848_bib131","unstructured":"C.A. Morris, S. Redican, S. Spector, C. Shanks, K.J. Brown, S. Schneider, J. Patrick Gonzalez (2021). IGNITE-DMD Phase I\/II Study of SGT-001 Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy. In A. 24th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) 2021 - Molecular Therapy, Volume 29, Issue 4, Supplement 1, S135, ed."},{"key":"10.1016\/j.omta.2026.201848_bib132","unstructured":"Solid Biosciences. SGT-003 INSPIRE DUCHENNE DATA UPDATE [Internet]. 2025. Available from: [https:\/\/investors.solidbio.com\/static-files\/8019db06-505b-4821-ba0f-4a39d037675d]."},{"key":"10.1016\/j.omta.2026.201848_bib133","unstructured":"Muntoni F., Shin J, Guglieri M, Stettner G, Veerapandiyan A, Gallo S, Shi H, Gundapaneni B, Neelakantan S, Lobello K, et al. (2024). CIFFREO, a phase 3, randomized, double-blind, placebo-controlled study of fordadistrogene movaparvovec (FM) in ambulatory participants with Duchenne muscular dystrophy (DMD). 29th International Annual Congress of the World Muscle Society (WMS) 2024 - Neuromuscular Disorders."},{"key":"10.1016\/j.omta.2026.201848_bib135","series-title":"Etranacogene Dezaparvovec [European public assessment report]: CSL Behring GmbH","year":"2023"},{"key":"10.1016\/j.omta.2026.201848_bib136","unstructured":"BEQVEZTM (Fidanacogene Elaparvovec-Dzkt) [ema European Public Assessment Report]. : Pfizer Europe MA EEIG; 2024."},{"key":"10.1016\/j.omta.2026.201848_bib137","unstructured":"Suter B., L.D., Benke T., Neul J., Jaggumantri S., Feng C., Albanis E., Cobb S., Jordan J. (2024). Preliminary Safety Results from the Ph1\/2 Study of NGN-401, a Novel Regulated Gene Therapy for Rett Syndrome. American Society of Gene and Cell Therapy."},{"key":"10.1016\/j.omta.2026.201848_bib138","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1016\/j.nmd.2022.07.234","article-title":"FP. 28 IGNITE DMD phase I\/II study of SGT-001 microdystrophin gene therapy for DMD: Long-term outcomes and expression update","volume":"32","author":"Dreghici","year":"2022","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omta.2026.201848_bib139","unstructured":"LogicBio Therapeutics, Inc. Gene Therapy With hLB-001 in Pediatric Patients With Severe Methylmalonic Acidemia (SUNRISE) [Internet]. ClinicalTrials.gov; NCT04581785. 2024 Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04581785."},{"key":"10.1016\/j.omta.2026.201848_bib140","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/00185787231182562","article-title":"Onasemnogene abeparvovec: post-infusion efficacy and safety in patients with spinal muscular atrophy (SMA)\u2014a fondazione policlinico gemelli IRCCS experience","volume":"59","author":"Favia","year":"2024","journal-title":"Hosp. Pharm."},{"key":"10.1016\/j.omta.2026.201848_bib141","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3390\/ph17030394","article-title":"Real-world safety data of the orphan drug onasemnogene abeparvovec (Zolgensma\u00ae) for the SMA rare disease: a pharmacovigilance study based on the EMA adverse event reporting system","volume":"17","author":"Ruggiero","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.omta.2026.201848_bib142","series-title":"23rd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT 2020) - Molecular Therapy","article-title":"Use of Prophylactic Steroids to Mitigate Potential T-Cell Response in AAV8-Mediated hLDLR Gene Transfer in Subjects with Homozygous Familial Hypercholesterolemia","author":"Marina Cuchel","year":"2020"},{"key":"10.1016\/j.omta.2026.201848_bib143","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1001\/jama.2023.3371","article-title":"Diagnosis and Treatment of Acute Myocarditis: A Review","volume":"329","author":"Ammirati","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.omta.2026.201848_bib144","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/FJC.0000000000001542","article-title":"Current Treatment and Immunomodulation Strategies in Acute Myocarditis","volume":"83","author":"Ferone","year":"2024","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.omta.2026.201848_bib145","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1089\/hum.2020.167","article-title":"Adeno-Associated Virus-Induced Dorsal Root Ganglion Pathology","volume":"31","author":"Hordeaux","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201848_bib146","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201848_bib147","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba9188","article-title":"MicroRNA-mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV vectors in primates","volume":"12","author":"Hordeaux","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omta.2026.201848_bib148","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2005056","article-title":"SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS","volume":"383","author":"Mueller","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201848_bib149","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.omtm.2022.03.017","article-title":"Circulating neurofilament light chain as a promising biomarker of AAV-induced dorsal root ganglia toxicity in nonclinical toxicology species","volume":"25","author":"Fader","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201848_bib150","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0167-5699(96)10066-9","article-title":"The influence of virus structure on antibody responses and virus serotype formation","volume":"17","author":"Bachmann","year":"1996","journal-title":"Immunol. Today"},{"key":"10.1016\/j.omta.2026.201848_bib151","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101273","article-title":"Global seroprevalence of neutralizing antibodies against adeno-associated virus serotypes used for human gene therapies","volume":"32","author":"Chhabra","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201848_bib152","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25021050","article-title":"Delivery of Adeno-Associated Virus Vectors to the Central Nervous System for Correction of Single Gene Disorders","volume":"25","author":"Daci","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omta.2026.201848_bib153","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/gt.2017.95","article-title":"Strategy to detect pre-existing immunity to AAV gene therapy","volume":"24","author":"Falese","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.omta.2026.201848_bib154","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1208\/s12248-019-0403-1","article-title":"Recommendations for the Development of Cell-Based Anti-Viral Vector Neutralizing Antibody Assays","volume":"22","author":"Gorovits","year":"2020","journal-title":"AAPS J."},{"key":"10.1016\/j.omta.2026.201848_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2025.103321","article-title":"Etranacogene dezaparvovec in people with hemophilia B and without adeno-associated virus serotype 5 neutralizing antibodies: a 4-year subgroup analysis of the Health Outcomes with Padua Gene; Evaluation in Hemophilia B (HOPE-B) trial","volume":"10","author":"Raheja","year":"2026","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/j.omta.2026.201848_bib156","article-title":"Etranacogene dezaparvovec in people with hemophilia B with preexisting adeno-associated virus 5 neutralizing antibodies: 4-year subgroup results from the HOPE-B trial","volume":"10","author":"Klamroth","year":"2026","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/j.omta.2026.201848_bib157","series-title":"Pfizer Announces Amendment to Ongoing Gene Therapy Phase III","author":"Dystrophy","year":"2021"},{"key":"10.1016\/j.omta.2026.201848_bib158","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/01926233241298892","article-title":"Systemic Toxicity of Recombinant Adeno-Associated Virus Gene Therapy Vectors","volume":"52","author":"Assaf","year":"2024","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.omta.2026.201848_bib159","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.ackd.2015.08.004","article-title":"Structural and Functional Changes With the Aging Kidney","volume":"23","author":"Denic","year":"2016","journal-title":"Adv. Chron. Kidney Dis."},{"key":"10.1016\/j.omta.2026.201848_bib160","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.exger.2017.10.024","article-title":"Age and immunity: What is \u201cimmunosenescence\u201d","volume":"105","author":"Pawelec","year":"2018","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.omta.2026.201848_bib161","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(12)62167-9","article-title":"Frailty in elderly people","volume":"381","author":"Clegg","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.omta.2026.201848_bib162","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/gt.2010.157","article-title":"Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver","volume":"18","author":"Qiao","year":"2011","journal-title":"Gene Ther."},{"key":"10.1016\/j.omta.2026.201848_bib163","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ymthe.2020.01.026","article-title":"Codon Modification and PAMPs in Clinical AAV Vectors: The Tortoise or the Hare?","volume":"28","author":"Wright","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201848_bib164","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.672449","article-title":"Effect of CpG Depletion of Vector Genome on CD8(+) T Cell Responses in AAV Gene Therapy","volume":"12","author":"Bertolini","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201848_bib165","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.omta.2026.201848_bib166","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201848_bib167","first-page":"2","article-title":"Can mTOR inhibitors reduce the risk of late kidney allograft failure?","volume":"21","author":"Ponticelli","year":"2008","journal-title":"Transpl. Int."},{"key":"10.1016\/j.omta.2026.201848_bib168","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1089\/hum.2022.138","article-title":"Immune Responses and Immunosuppressive Strategies for Adeno-Associated Virus-Based Gene Therapy for Treatment of Central Nervous System Disorders: Current Knowledge and Approaches","volume":"33","author":"Prasad","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201848_bib170","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1016\/j.ymthe.2024.07.016","article-title":"A systematic review of immunosuppressive protocols used in AAV gene therapy for monogenic disorders","volume":"32","author":"Vrellaku","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201848_bib171","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1093\/cvr\/cvaf200","article-title":"First-in-human study of TN-201, an AAV9 gene replacement therapy in MYBPC3-associated hypertrophic cardiomyopathy: initial safety, pharmacodynamic, and imaging results from MyPEAK-1","volume":"121","author":"Desai","year":"2025","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.omta.2026.201848_bib172","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1056\/NEJMoa2412392","article-title":"Phase 1 Study of AAV9.LAMP2B Gene Therapy in Danon Disease","volume":"392","author":"Greenberg","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201848_bib169","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s13365-018-0615-7","article-title":"Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event","volume":"24","author":"Berger","year":"2018","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.omta.2026.201848_bib173","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3389\/fimmu.2018.00554","article-title":"Gene Therapy With Regulatory T Cells: A Beneficial Alliance","volume":"9","author":"Biswas","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201848_bib174","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune Responses to Viral Gene Therapy Vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201848_bib175","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1182\/blood-2018-07-820720","article-title":"Update on clinical gene therapy for hemophilia","volume":"133","author":"Perrin","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201848_bib176","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139881","article-title":"Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme","volume":"5","author":"Elmore","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.omta.2026.201848_bib177","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","article-title":"IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies","volume":"26","author":"Leborgne","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2026.201848_bib178","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.omtm.2022.12.012","article-title":"Neurofilament light chain and dorsal root ganglia injury after adeno-associated virus 9 gene therapy in nonhuman primates","volume":"28","author":"Johnson","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201848_bib179","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.omtm.2019.05.009","article-title":"Therapeutic hFIX Activity Achieved after Single AAV5-hFIX Treatment in Hemophilia B Patients and NHPs with Pre-existing Anti-AAV5 NABs","volume":"14","author":"Majowicz","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201848_bib180","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.ymthe.2020.07.006","article-title":"Quantification of CpG Motifs in rAAV Genomes: Avoiding the Toll","volume":"28","author":"Wright","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201848_bib181","doi-asserted-by":"crossref","first-page":"844","DOI":"10.3389\/fimmu.2018.00844","article-title":"Efficient Capsid Antigen Presentation From Adeno-Associated Virus Empty Virions In Vivo","volume":"9","author":"Pei","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201848_bib182","author":"Pharmaceuticals"},{"key":"10.1016\/j.omta.2026.201848_bib183","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.12491.1","article-title":"Emerging therapies for hemophilia: controversies and unanswered questions","volume":"7","author":"Arruda","year":"2018","journal-title":"F1000Res."}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26001837?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26001837?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:15:25Z","timestamp":1791058525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X26001837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":181,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S3117387X26001837"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2026.201848","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical immunogenicity in rAAV gene therapy: Insights and implications","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2026.201848","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201848"}}